复方紫草油治疗唇炎机制的网络药理学研究

目的：利用网络药理学的技术探索复方紫草油治疗唇炎的机制,为后续实验研究及扩大复方紫草油的适应证提供理论基础。方法：依托中药系统药理学平台(TCMSP)、中药综合数据库（TCMID）筛选复方紫草油的有效化合物和作用靶点;通过检索人类基因信息数据库（GeneCards）及人类孟德尔遗传研究平台（OMIM）选取唇炎的疾病靶点,并利用R语言取疾病与药物靶点交集;应用Cytoscape软件构建药物-化合物-靶点-疾病互作网络;运用STRING平台搭建蛋白质间相互作用网络（PPI）;使用Bioconductor生物信息软件包进行GO功能富集和KEGG通路分析。结果：筛选得103个化合物和相应115个靶点,其中有21个与疾病相关。GO功能富集分析得到22个条目,KEGG通路富集分析筛选得到91条信号通路。结论：复方紫草油治疗唇炎具有生物学支撑。不同的蛋白存在协同作用,其中IL-6、STAT3和TNF等靶点起着关键作用。生物过程主要涉及细胞因子受体结合、金属内肽酶活性等,并主要富集在AGE-RAGE、FssAs和TNF等多条信号通路上,发挥抗炎及调控细胞增殖和凋亡等作用。     

平阳霉素联合激素治疗肉芽肿性唇炎的临床疗效评价

目的: 探讨平阳霉素联合激素治疗肉芽肿性唇炎的临床疗效。 方法: 选取2008年3月—2016年3月在济南军区总医院口腔科就诊的肉芽肿性唇炎患者78例,行平阳霉素联合激素局部注射治疗,对治疗前、后的病例进行对比,评价治疗效果。 结果: 肉芽肿性唇炎患者78例,均接受了对患唇的平阳霉素联合地塞米松局部注射治疗,治疗次数1~5次不等,平均3次。73例患者治愈,5例好转。所有病例唇肿胀均得到改善,部分病例面部肿胀亦得到一定程度缓解。 结论: 平阳霉素联合激素局部注射治疗肉芽肿性唇炎,安全、经济、有效,能改善唇部顽固性肿胀并达到理想的美观效果。     

p53 AND MDM2 PROTEIN EXPRESSION IN ACTINIC CHEILITIS

Actinic cheilitis is a potentially malignant lip lesion caused by excessive and prolonged exposure to ultraviolet radiation, which can lead to histomorphological alterations indicative of abnormal cell differentiation. In this pathology, varying degrees of epithelial dysplasia may be found. There are few published studies regarding the p53 and MDM2 proteins in actinic cheilitis. Fifty-eight cases diagnosed with actinic cheilitis were histologically evaluated using Banóczy and Csiba (1976) parameters, and were subjected to immunohistochemical analysis using the streptavidin-biotin method in order to assess p53 and MDM2 protein expression. All studied cases expressed p53 proteins in basal and suprabasal layers. In the basal layer, the nuclei testing positive for p53 were stained intensely, while in the suprabasal layer, cells with slightly stained nuclei were predominant. All cases also tested positive for the MDM2 protein, but with varying degrees of nuclear expression and a predominance of slightly stained cells. A statistically significant correlation between the percentage of p53 and MDM2-positive cells was established, regardless of the degree of epithelial dysplasia. The expression of p53 and MDM2 proteins in actinic cheilitis can be an important indicator in lip carcinogenesis, regardless of the degree of epithelial dysplasia.     

Cheilitis granulomatosa and Melkersson–Rosenthal syndrome: evaluation of gastrointestinal involvement and therapeutic regimens in a series of 14 patients

BACKGROUND: Cheilitis granulomatosa and Melkersson-Rosenthal syndrome are both rare and benign diseases. Because of their granulomatous character, a relationship to Crohn's disease has been suggested. Furthermore, because of their unknown aetiology, treatment is difficult, and evaluation of response is hampered by the natural tendency to spontaneous resolution and recurrence. OBJECTIVES AND METHODS: To evaluate gastrointestinal involvement by clinical history, conventional endoscopy, and capsule endoscopy as well as to compare efficacy of treatment modalities on a series of 14 patients, one of the biggest collectives reported. RESULTS: Four patients (4 of 14) were previously, simultaneously, or subsequently diagnosed with Crohn's disease. In six patients (6 of 14) with minor gastrointestinal symptoms as flatulence, occasional constipation, diarrhoea, or admixture of mucus with the stool, we could not detect any signs of inflammatory bowel disease by capsule endoscopy. Nine patients received clofazimine, and eight patients responded to treatment (four complete responses, four partial responses). Two patients were successfully treated with infliximab. Systemic methylprednisone was not successful in two patients. CONCLUSION: Close to 30% of patients showed an association of cheilitis granulomatosa and Crohn's disease. Forty-three per cent of patients reported minor gastrointestinal irregularities without any detectable changes of Crohn's disease. Clofazimine seems to be an effective treatment, although long-term application is necessary with frequent aggravation in the beginning. Infliximab, an effective drug in Crohn's disease, could be a promising treatment option for severe cases.     

Clinical features of atopic dermatitis and a family history of atopy

In 365 children and 213 adults the characteristics of atopic dermatitis isolated by Hanifin and Rajka were analysed in relation to a family history of allergy. A positive history in both parents and/or their families was associated with higher IgE titres, earlier appearance of skin changes, more frequent occurrence of urticaria, allergic respiratory diseases, cheilitis, and, in women, nipple eczema. These changes were less frequent and the IgE titre was lower in patients with one atopic parent, and even less frequent (or lower IgE titre) in patients with no family history of atopic disease, although the latter difference was sometimes slight.     

Allergic cheilitis to azulene

A 26-year-old woman developed redness, scaling, cracking and dryness of the vermillion and skin surrounding the lips. She had used the same toothpaste (AZ-15®) for some years. The clinical manifestations cleared rapidly with avoidance of the toothpaste and topical steroid therapy.     

CO2-Laservaporisation der Cheilitis actinica

Zusammenfassung Für die Cheilitis actinica gilt wegen ihrer Zugeh?rigkeit zu den fakultativen Pr?kanzerosen eine obligate Behandlungsindikation, wobei verschiedenste, mehr oder weniger invasive Therapieverfahren zur Anwendung kommen. In dieser Arbeit soll speziell auf die M?glichkeit der CO₂-Laservaporisation hingewiesen werden, die, im Gegensatz zur englischsprachigen, in der deutschsprachigen Fachliteratur bislang keine nennenswerte Beachtung gefunden hat. Wir berichten über eigene Behandlungsergebnisse bei 19 CO₂-Laserbehandlungen bei Cheilitis actinica. In nur einem Fall erwies sich die erste Behandlung als zu oberfl?chlich für eine vollst?ndige Abheilung. Bei einer mittleren Nachbeobachtungszeit von 16 Monaten konnten keine weiteren Rezidive und in nur einem Fall eine unauff?llige Narbenbildung beobachtet werden. Im Vergleich zu anderen Behandlungsm?glichkeiten, die kurz dargestellt werden, kann die CO₂-Laserablation als sicheres und kostengünstiges Verfahren mit exzellentem kosmetischen Ergebnis angesehen werden.      

4种常用免疫抑制剂对器官移植术后口腔临床表现的影响

目的： 通过观察分析肝、肾或造血干细胞移植术后口腔临床表现,探讨移植术后4种常用免疫抑制剂对口腔临床表现的影响。方法： 收集118例接受4种常用免疫抑制剂他克莫司、西罗莫司、环孢素或吗替麦考酚酯的实体器官或造血干细胞移植术后患者,采用问卷调查、口腔临床检查,记录患者术后口腔临床表现和免疫抑制剂的使用情况,并采用SPSS 21.0软件包对数据进行统计学分析。结果： 术后使用他克莫司的患者,口腔苔藓样病变和唇炎的发生率均显著低于未使用他克莫司组（P<0.01）;术后使用环孢素的患者,口腔苔藓样病变的发生率显著高于未使用环孢素组（P<0.05）,且唇炎的发生率显著高于未使用环孢素组（P<0.01）;术后使用他克莫司的患者,苔藓样病变、唇炎的发生率均显著低于使用环孢素组（P<0.01);术后使用吗替麦考酚酯的患者,自觉口干的发生率显著低于未使用吗替麦考酚酯组（P<0.01）;术后使用西罗莫司的患者,口腔临床表现发生率无明显降低。结论： 移植术后使用他克莫司,可改善口腔苔藓样病变和唇炎的症状,效果优于环孢素。使用吗替麦考酚酯可改善患者自觉口干症状。     

Melkersson-Rosenthal syndrome

Melkersson-Rosenthal syndrome (MRS) is a rare, non-caseating granulomatous disorder of unknown etiology and undefined diagnostic criteria. The classical triad of recurrent orofacial edema, relapsing facial paralysis, and fissured tongue, is not frequently seen in its complete form, and many patients remain misdiagnosed or undiagnosed for years. The purpose of this study is to review the findings in the literature describing the Melkersson-Rosenthal syndrome with aim to identify its clinical and histopathological characteristics and correlate them with definitive diagnostic criteria and effective treatment modalities. A systematic review and analysis of more than 100 publications met eligibility criteria performed by the authors. Orofacial edema of unknown etiology is the most typical clinical feature of the Melkersson-Rosenthal syndrome. Its coexistence with of facial nerve palsy or fissured tongue could be characterized as an oligosymptomatic MRS. Many investigators suggest cheilitis granulomatosa as a monosymptomatic form of MRS, while patients with facial palsy and fissured tongue, without orofacial edema, should not be considered having MRS. Histological evidence is not necessary. Corticosteroids are generally accepted as the mainstay treatment.     

多种维生素胶丸油液和高原护肤霜预防急性高原性唇炎的效果观察

目的：观察多种维生素胶丸油液和高原护扶霜预防急性高原生唇炎的效果。方法：对进驻海拔５１００ｍ高原野外施工的２１２名部队青年随机分３组，分别涂用多种维生素油液（１１２人）、高原护扶霜（５０人）和空白对照组（５０人），随访１天￣１５天唇炎发病情况，并在平原室内用紫外线照射仪对上述受试者中６名进行紫外线照射，部位取前臂中段内侧１．５ｃｍ＾２皮肤三处，分别涂维生素油液、护扶霜和覆盖扩光纸。紫外线剂量为最小